Targeting Cancer Recurrence and Metastasis
The Evolving Understanding of Cancer Stem Cells
At the Forefront of Innovative Research

About Us

At Boston Biomedical, our mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stem cell pathways.

Product Pipeline

home_pipeline_img (1)

BBI608, currently in Phase III development, is an orally administered investigational agent that targets the STAT3 pathway, a critical pathway in cancer stemness.

Tell me more